Comparison Overview
DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs
DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs
N/A
Last Update: 22/04/2026
Please see Important Safety Information below in the pinned post and at https://www.darzalexhcp.com/ISI. This product information is intended for US Healthcare Professionals only. DARZALEX® and DARZALEX FASPRO® are products of Janssen Biotech, Inc., and are not asso...
MACLEODS PHARMACEUTICALS LTD.
304, Atlanta Arcade Marol Church Road, Mumbai, 400059, IN
Last Update: 30/03/2026
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermato...
Compliance Ranges Comparison
DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs
MACLEODS PHARMACEUTICALS LTD.
Benchmark & Cyber Underwriting Signals
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs in 2026.
Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)
No incidents recorded for MACLEODS PHARMACEUTICALS LTD. in 2026.
Incident History - DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs (X = Date, Y = Severity)
DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs cyber incidents detection timeline including parent company and subsidiaries.
Incident History - MACLEODS PHARMACEUTICALS LTD. (X = Date, Y = Severity)
MACLEODS PHARMACEUTICALS LTD. cyber incidents detection timeline including parent company and subsidiaries.
Notable Incidents
DARZALEX® (daratumumab) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for HCPs
MACLEODS PHARMACEUTICALS LTD.
FAQ
Latest Global CVEs
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an inadequate encryption strength vulnerability which could allow an attacker to steal admin credentials via weak hash or a pass-the-hash attack.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could allow for asset discovery by unauthenticated users.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an unintended proxy or intermediary vulnerability which could allow an attacker to use an active proxy, which would bypass OT segmentation.
Pronetiqs IntraVUE Versions 3.2.1a14 and prior have a plaintext storage of a password vulnerability that could expose cleartext credentials through the API.
Pronetiqs IntraVUE versions 3.2.1a14 and prior have an exposure of sensitive system information to an unauthorized control sphere vulnerability which could expose the underlying host/share filesystem.